Takeda partners with Neurocrine Biosciences to focus on psychiatric disorders
Singapore, June 17 -- US based Neurocrine Biosciences, Inc. and Japanese firm Takeda Pharmaceutical Company Limited have announced a strategic collaboration to develop and commercialize compounds in Takeda's early-to-mid-stage psychiatry pipeline.
Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.
Under the terms of the agreement, Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration.
Takeda will receive a total of $120 million USD in upfront cash. Additionally, Takeda will be entitled to development miles...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.